That 16-pin connector tucked beneath the dashboard of every car built after 1996 is one of the most underused tools available ...

Finding high-performing catalysts, which are used to accelerate processes from chemical manufacturing to energy production, ...

Incyte remains attractively valued, trading at 12.5x 2026 EPS, well below sector medians, with 9% EPS and revenue growth expected. Jakafi, currently 60% of revenue, faces patent expiration in 2028; ...

LyondellBasell (LYB) is a leading global producer of plastics, chemicals, and refining products, with a dominant position in polypropylene and polyethylene markets. The company benefits from a ...

Citi has resumed coverage of streaming giant Netflix (NFLX) with an investment rating of “buy” following the bidding war against Paramount (PSKY) for the assets of Warner Bros. (WBD). The research ...

SanDisk (SNDK) stock fell 5% to less than $740 even though the company has reported Q4 revenue of $3.025B, up 61% year-over-year. The selloff reflects competitive supply concerns from Micron ...

In other recent news, United Therapeutics has been the focus of several analyst updates following its latest developments. UBS has increased its price target for United Therapeutics to $705 from $655, ...

Is BIP a good stock to buy? We came across a bullish thesis on Brookfield Infrastructure Partners L.P. on David & Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on ...

Pepeto announces that its latest presale stage has completely sold out, pushing the project into its next pricing tier as demand continues to outpace every previous round. This is the fastest any ...

In this article, we will discuss: Jim Cramer’s Hottest Nuclear Energy Stock Picks, Hits & Misses. For more stocks, you can head to Jim Cramer’s Hottest Nuclear Energy Stock Picks, Hits & Misses: Top 5 ...

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 ...

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.